Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarveda Therapeutics Inc.

www.tarveda.com

Latest From Tarveda Therapeutics Inc.

Pipeline Watch: Phase III Progress With Nimotuzumab, Solriamfetol, And Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Approvals Research & Development

Finance Watch: Happy Holidays For Flagship With A New $618m Fund

Private Company Edition: Flagship ends 2017 with its biggest life science fund yet totaling $618m. Also, December sees a year-end surge in VC deals, including a $100m Series B round for Allakos.

Financing StartUps and SMEs

Appointments: GSK, Neurocrine Biosciences, Cue Biopharma, BenevolentAI And Ferring Pharmaceuticals

This week's roundup includes two executive appointments by GSK, plus updates from Radius Health Inc., Cue Biopharma and BenevolentAI, with Myovant Sciences making four key management hires.

Appointments BioPharmaceutical

Miniature By Design: Tarveda's Small Conjugates Could Be Better Fit For HSP90

Biotech's internally derived Pentarins offer the targeting advantages of antibody-drug conjugates in cancer, but with better affinity, pharmacokinetics and deeper tumor penetration.

Platform Technologies Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Blend Therapeutics Inc.
  • Blend Biosciences Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tarveda Therapeutics Inc.
  • Senior Management
  • Drew Fromkin, Pres. & CEO
    Brian Roberts, CFO
    Richard Wooster, PhD, Pres., R&D & CSO
    Sudha Kadiyala , PhD, SVP, Strategy & Dev.
  • Contact Info
  • Tarveda Therapeutics Inc.
    Phone: (617) 923-4100
    134 Coolidge Ave.
    Watertown, MA 02472
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register